At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
|Videos|July 22, 2017
Despite a Challenging Market, Tools Available for Independent Pharmacists
The challenges are well-documented, but additional acccess to data is assisting the independent pharmacist.
Advertisement
In this video clip taken at ThoughtSpot 2017, Charlie Le Bon, who is Director of Pharmacy Ownership with AmerisourceBergen, discusses the tools that are available to independent pharmacy owners to help them succeed, even in a challenging market.
Advertisement
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
5